Pharma Foods International Co., Ltd.
Forecast Revision for the Full Year Ending July 2026
Revised full-year figures to: net sales of 63,200 million yen, operating income 2,600 million yen, ordinary income 2,400 million yen, net income attributable to owners of the parent 1,950 million yen. Despite a year-on-year decline in sales by 3,800 million yen from the previous forecast, profits are raised. Under the mid-term plan, the promotion of the New Value Creation 1K Project aims to maintain solid profitability across core businesses.
Key Figures
- 63,200: Net sales (million yen)
- 2,600: Operating income (million yen)
- 2,400: Ordinary income (million yen)
AI要約
Key points of the news
Based on the mid-term management plan, New Value Creation 1K Project, we will promote innovation in the healthcare sector and development of high-value-added products. We revise the full-year forecast for this term; sales are expected to be below the previous forecast, but profit items are raised, shifting management to prioritize financial soundness and capital efficiency.
Outlook and impact on investors
Profitability improvements are pursued across each business, including pharma-gaba in the BtoB domain with expanding recruitment, BtoC products including New Value Creation 1K Project series, and broader industrial applications of Oboveur. Collaborative development with National Center for Global Health and Medicine indicates research and development activity. The plan is to continue expanding sales scale while prioritizing higher profitability and capital efficiency.
Pharma Foods International Co., Ltd.
Company overview · Stock price · Financial data · All IR
